Carcinoma in Situ, Dysplasia, Head and Neck, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Hyperplasia, Premalignant Lesion, Tobacco-Related Carcinoma
Conditions
Keywords
prevention, dietary supplement, broccoli, avmacol
Brief summary
Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, participants who have been curatively treatment for head and neck cancer, will take Avmacol twice a day for 3 months.
Detailed description
The broccoli seed preparation, Avmacol®, results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related head and neck squamous cell carcinoma (HNSCC), including high grade dysplasia, carcinoma in situ, or invasive carcinoma. This study is not designed to examine the therapeutic or reparative effects of Avmacol® on premalignant lesions of the oral cavity. We will systematically assess the clinical chemopreventive potential of Avmacol® administration to patients with tobacco-related HNSCC at high risk for second primary tumor by: 1. Conducting this phase 0 clinical study to evaluate the pharmacodynamic range of NRF2 pathway activation in the oral mucosa of HNSCC patients, in response to two tolerable and bioactive doses of Avmacol®; 2. Determining whether the level of NRF2 pathway activation achieved in human oral epithelium is chemopreventive in the NQO1 murine model of environmental carcinogenesis; and 3. Analyzing specimens from the Phase 0 trial to determine whether Avmacol® induces changes in alternative biomarkers of SF chemopreventive efficacy identified in the laboratory.
Interventions
DIETARY_SUPPLEMENTAvmacol
Avmacol is a dietary supplement available over the counter
Sponsors
National Cancer Institute (NCI)
University of Arizona
University of Pittsburgh
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Thirty-six individuals who have previously been treated for tobacco-related, HPV-negative HNSCC will be recruited for this study. After being deemed eligible, subjects will be assigned a patient number and be registered into the CTMA database. At registration, they will be randomized to receive either 4 tablets/day in Cycle 1 or 8 tablets/day in Cycle 1 (and the other dose in Cycle 2). This randomization is not blinded. Randomization will be stratified by history of head and neck radiation therapy (yes or no).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants must have completed curative-intent therapy (including surgery, radiation, and/or chemotherapy) for a first tobacco-related oral premalignant lesion (OPL) or HNSCC of any stage (eligible lesions include high grade dysplasia; carcinoma in situ; or stage I-IVa HNSCC). 2. Primary site may include oral cavity, pharynx, or larynx. Oropharynx primaries must be HPV (-) as defined by routine p16 IHC at the local site. 3. Participants may be enrolled between 3 months and 5 years AFTER completion of curative-intent therapy (including surgery, radiotherapy, and/or chemotherapy). 4. Participants may have untreated OPLs (i.e., hyperplasia, dysplasia, carcinoma in situ) at the time of study entry, provided the index OPL or HNSCC was definitively treated. 5. Participants must be at least 18 years old. 6. Participants must have a Karnofsky Performance Status of 80% or higher or an ECOG of 0-1 (Appendix A). 7. Current and former tobacco users are eligible. The tobacco use assessment form must be completed following consent, to assure eligibility (Appendix B). Patients must have ≥10 pack-year cumulative tobacco exposure or its equivalent to be eligible. This is defined as follows: 1. Cigarette exposure: ≥10 pack-years OR 2. Cigar exposure: ≥ 10 cigar-years, where 1 cigar year is defined as having smoked on average ≥ 1 cigar/day for a year OR 3. Chewing tobacco: ≥10 snuff-years, where 1 snuff year is defined as using on average ≥ 1 pinch (dip) of chewing tobacco/day for a year. 8. Able to perform written, informed consent. 9. Women of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 Days prior to the first study intervention. 10. WCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation.
Exclusion criteria
1. Participants have a history of another malignancy within 2 years prior to starting study treatment, except for excised and cured carcinoma-in-situ of breast or cervix; non-melanomatous skin cancer; T1-2, N0, M0 differentiated thyroid carcinoma either resected or under active surveillance; superficial bladder cancer; T1a or T1b prostate cancer comprising \< 5% of resected tissue with normal prostate specific antigen (PSA) since resection, or status post external beam radiation or brachytherapy with normal PSA since radiation. 2. Primary oropharyngeal HNSCC which is HPV (+) as defined by p16 IHC. 3. Participants with acute intercurrent illness or those who had major surgery within the preceding 4 weeks unless they have fully recovered. 4. Participants who have a positive pregnancy test, are pregnant, or breast feeding. 5. Patients who are not practicing adequate contraception are ineligible if they are of child bearing potential. 6. Patients currently using anti-neoplastic or anti-tumor agents, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy. 7. Chronic anticoagulation with warfarin. Patients on low molecular weight heparin or fondaparinux may be enrolled. 8. Use of chronic prescribed medications which are potent inducers or inhibitors of CYP3A4 (Appendix C). 9. Chronic use of steroids at immunosuppressive doses. (Note, physiologic replacement doses of glucocorticoid or mineralocorticoid are acceptable, eg. prednisone 5-10 mg/day; fludrocortisone 0.1-0.2 mg/day.) 10. History of severe food intolerance to broccoli.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in NRF2 target gene expression | From baseline throughout treatment period, up to 4 months | Quantitative changes in NRF2 target gene transcripts expression (i.e. NQO1 and GCLC) in oral mucosa (buccal cytobrush) by quantitative polymerase chain reaction (qPCR) according to a linear mixed model framework. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in NRF2 target gene transcripts | From baseline throughout treatment period, up to 4 months | Change in NRF2 target gene transcripts, between the two doses of Avmacol® by immunoblotting. |
| Change in NRF2 target proteins | From baseline throughout treatment period, up to 4 months | Changes in NRF2 target proteins in buccal punch biopsies by immunoblotting. |
| Alterations of Avmacol® activity in PBMCs - NK cells | From baseline throughout treatment period, up to 4 months | Changes in Peripheral Blood Mononuclear Cells (PBMC) gene expression and flow cytometry patterns in NK cells. |
| Alterations of Avmacol® activity in PBMCs - T cells | From baseline throughout treatment period, up to 4 months | Changes in Peripheral Blood Mononuclear Cells (PBMC) gene expression and flow cytometry patterns in T cells. |
| Change in NRF2-independent proteins | From baseline throughout treatment period, up to 4 months | Change in NRF2 target gene transcripts, between the two doses of Avmacol® by immunoblotting. |
| Measurement of serum albumin-bound SF | From baseline throughout treatment period, up to 4 months | Measurement of urinary metabolites of SF using isotope dilution mass spectrometry. |
| Safety profile in accordance with NCI CTCAE v.4 | Throughout treatment period, up to 4 months | Patients will receive a diary for daily logging of adverse events. This will tabulated by Avmacol dose and type and grade of adverse events. The mean frequency and grade of events will be calculated by dose, and between-dose differences compared by means |
| Proportion of patients primary tumors harboring genomic alteration of NRF2 related genes | At baseline | Genomic alterations in primary tumors will be characterized and the proportion determined by number of patients with NRF2 related genes per the total number of patients studied. |
| Change in serum cytokine levels | From baseline throughout treatment period, up to 4 months | Change in serum cytokine levels, as determined by multiplexed bead-based cytokine assays. |
Countries
United States
Outcome results
None listed